Cancer immune evasion is a major stumbling block in designing effective anticancer
therapeutic strategies. Although considerable progress has been made in understanding …

Background Advanced prostate cancer remains one of the most common and deadly
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …

Objective To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin
plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

It has recently become clear that the tumour microenvironment, and in particular the immune
system, has a crucial role in modulating tumour progression and response to therapy …

The successes achieved by chimeric antigen receptor-modified T (CAR-T) cells in
hematological malignancies raised the possibility of their use in non-small lung cancer …

The application of traditional chemotherapy drugs for lung cancer has obvious limitations,
such as toxic side effects, uncontrolled drug-release, poor bioavailability, and drug …

Purpose: Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and
are associated with immune suppression. To date, there have only been few studies that …

Cancer immunotherapy faces a serious challenge because of low clinical efficacy. Recently,
a number of clinical studies have reported the serendipitous finding of high rates of objective …

Background Chemotherapy combined with immunotherapy becomes the main trend in lung
cancer intervention; however, how chemotherapy promotes the immune function remains …